Related references
Note: Only part of the references are listed.How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments?
Bram Verstockt et al.
GASTROENTEROLOGY (2022)
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
William J. Sandborn et al.
GASTROENTEROLOGY (2022)
Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2022)
OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study
B E Sands et al.
Journal of Crohns & Colitis (2022)
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Waseem Ahmed et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael et al.
Lancet Gastroenterology & Hepatology (2022)
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
David T. Rubin et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
Silvio Danese et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD
Nurulamin M. Noor et al.
INFLAMMATORY BOWEL DISEASES (2022)
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
Konstantinos Papamichael et al.
BMJ OPEN (2022)
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands et al.
LANCET (2022)
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center
Lukasz Kwapisz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease
Peter Bossuyt et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
John L. Lyles et al.
INFLAMMATORY BOWEL DISEASES (2021)
Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease
Giuseppe Privitera et al.
JOURNAL OF CROHNS & COLITIS (2021)
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis
Konstantinos Papamichael et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
Anne S. Strik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
Sare Verstockt et al.
INFLAMMATORY BOWEL DISEASES (2021)
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Daniel C. Baumgart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study
Laurent Goessens et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
Eran Zittan et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2021)
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease
Carlos Stalgis et al.
GASTROENTEROLOGY (2021)
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
Siddharth Singh et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Breaking the therapeutic ceiling in drug development in ulcerative colitis
Dahham Alsoud et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease
Omeed Alipour et al.
BMC GASTROENTEROLOGY (2021)
Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease
Michael T. Dolinger et al.
INFLAMMATORY BOWEL DISEASES (2021)
Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response
Miles P. Sparrow et al.
JOURNAL OF CROHNS & COLITIS (2020)
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
Aleksejs Sazonovs et al.
GASTROENTEROLOGY (2020)
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease
Edward Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Kerri Glassner et al.
JOURNAL OF DIGESTIVE DISEASES (2020)
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
Christine Olbjorn et al.
PEDIATRIC DRUGS (2020)
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
Sine Buhl et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?
Bram Verstockt et al.
GUT (2019)
Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children
Wael El-Matary et al.
INFLAMMATORY BOWEL DISEASES (2019)
T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence
Matthieu Allez et al.
GUT (2019)
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
Gareth J. Walker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients
Kathryn Clarkston et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
Bram Verstockt et al.
EBIOMEDICINE (2019)
A blood-based prognostic biomarker in IBD
Daniele Biasci et al.
GUT (2019)
Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment
Ting Feng et al.
INFLAMMATORY BOWEL DISEASES (2019)
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis
Davide Giuseppe Ribaldone et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Konstantinos Papamichael et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis
Niels Vande Casteele et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Maria Chaparro et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease
Ben Kang et al.
JOURNAL OF CROHNS & COLITIS (2019)
Personalised medicine in Crohn's disease
Nurulamin M Noor et al.
Lancet Gastroenterology & Hepatology (2019)
Remicade® (infliximab): 20 years of contributions to science and medicine
Richard Melsheimer et al.
BIOLOGICS-TARGETS & THERAPY (2019)
Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming
Diane R. Mould et al.
AAPS JOURNAL (2018)
Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study
Bella Ungar et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
Erwin Dreesen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2018)
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Lydia C. T. Buer et al.
INFLAMMATORY BOWEL DISEASES (2018)
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Siddharth Singh et al.
JOURNAL OF CROHNS & COLITIS (2018)
PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial
Miles Parkes et al.
BMJ OPEN (2018)
Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target
Ben Kang et al.
PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION (2018)
Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease
Yana Davidov et al.
JOURNAL OF CROHNS & COLITIS (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study
Xavier Roblin et al.
INFLAMMATORY BOWEL DISEASES (2017)
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel et al.
LANCET (2017)
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Nathaniel R. West et al.
NATURE MEDICINE (2017)
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months
Nicolas Williet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials
A. Cholapranee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
A. J. Yarur et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis
R. S. Choung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease
X. Zhu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease
Eran Zittan et al.
INFLAMMATORY BOWEL DISEASES (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease
Marieke J. H. Coenen et al.
GASTROENTEROLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases
Marla Dubinsky et al.
GASTROENTEROLOGY (2015)
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2015)
Dashboard Systems: Pharmacokinetic/Pharmacodynamic Mediated Dose Optimization for Monoclonal Antibodies
Diane R. Mould et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna et al.
LANCET (2015)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele et al.
GUT (2015)
Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis
F. Baert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Catching the Therapeutic Window of Opportunity in Early Crohn's Disease
Silvio Danese et al.
CURRENT DRUG TARGETS (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Suk-Kyun Yang et al.
NATURE GENETICS (2014)
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging
William A. Faubion et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes
Alain M. Schoepfer et al.
INFLAMMATORY BOWEL DISEASES (2013)
Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
Martine De Vos et al.
INFLAMMATORY BOWEL DISEASES (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Anti-Saccharomyces cerevisiae Antibodies Associate with Phenotypes and Higher Risk for Surgery in Crohn's Disease: A Meta-Analysis
Zhaoxia Zhang et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
Ren Mao et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
Geert D'Haens et al.
INFLAMMATORY BOWEL DISEASES (2012)
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis
James C. Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
What Is the Role of Serological Markers in IBD? Pediatric and Adult Data
Marla Dubinsky
DIGESTIVE DISEASES (2009)
Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease
A. Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
An Update on the Epidemiology of Inflammatory Bowel Disease in Asia
Kelvin T. Thia et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
Marc Ferrante et al.
GUT (2007)
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2007)
Share Paper
